原发骨弥漫大B细胞淋巴瘤患者的临床特征及预后分析  

Clinical Characteristics and Prognosis of Patients with Primary Bone Diffuse Large B-Cell Lymphoma

作　　者：冯友繁[1,2] 魏小芳 张启科 赵丽[2,3] 梁小芹[4] 伏媛 黄秀娟[1] 李青芬[1] FENG You-Fan;WEI Xiao-Fang;ZHANG Qi-Ke;ZHAO Li;LIANG Xiao-Qin;FU Yuan;HUANG Xiu-Juan;LI Qing-Fen(Department of Hematology,Gansu Provincial Hospital;The First Clinical Medical College of Lanzhou University;Gansu Key Laboratory of Genetic Study of Hematopathy;Department of Pathology,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China)

机构地区：[1]甘肃省人民医院血液科 [2]兰州大学第一临床医学院 [3]甘肃省血液病遗传研究重点实验室 [4]甘肃省人民医院病理科,甘肃兰州730000

出　　处：《中国实验血液学杂志》2021年第5期1517-1521,共5页Journal of Experimental Hematology

摘　　要：目的:探讨原发骨弥漫大B细胞淋巴瘤患者的临床特点及其预后。方法:收集甘肃省人民医院2013年1月至2020年12月收治的15例原发骨弥漫大B细胞淋巴瘤患者的临床资料,并对其临床特点及预后进行回顾性分析和总结。结果:15例患者的中位发病年龄为59(19-89)岁;男性7例,女性8例,首发症状均为骨痛;15例患者病理类型均为弥漫大B细胞淋巴瘤(DLBCL),Has分型GCB亚型5例(5/15),Non-GCB亚型10例(10/15)。15例患者中,11例(11/15)患者接受化疗,3例(3/15)患者接受手术治疗,1例患者未治疗(1/15),中位接受化疗疗程数为5(1-9)疗程。评估近期疗效,8例患者达CR(8/15),3例达PR(3/15),1例SD(1/15),1例失访(1/15),1例未治疗(1/15),1例PD(1/15)。年龄、病理亚型、性别、分期、β2-MG水平、LDH水平、是否应用利妥昔单抗与完全缓解率均无统计学相关性(P>0.05),IPI评分与近期完全缓解率相关(P<0.05)。中位随访时间19(1-38)个月,10例存活,其中6例仍完全缓解,中位无进展生存时间为15(1-38)个月。结论:原发骨弥漫大B细胞淋巴瘤首发症状以骨痛为主,病理亚型以Non-GCB为主,治疗以联合化疗为主,IPI评分与治疗预后相关。Objective:To investigate the clinical characteristics and prognosis of patients with primary bone diffuse large B-cell lymphoma.Methods:The clinical data of 15 patients with primary diffuse large B-cell lymphoma treated in our hospital from January 2013 to December 2020 were collected,the clinical data and prognosis of the patients were analyzed retrospectively.Results:The median age of the 15 patients was 59(19-89)years old;among the patients,7 were males and 8 were females,ostealgia was the initial symptom.The pathological types of the 15 patients were diffuse large B-cell lymphoma(DLBCL),5 cases of Has type GCB subtype(5/15),and 10 cases of Non-GCB subtype(10/15).After 15 patients were diagnosed,11 patients(11/15)received chemotherapy,3 patients(3/15)received surgery,and 1 patient was untreated(1/15),median chemotherapy courses was 5(1-9).8 patients have achieved complete remission(8/15),3 patients achieved partial remission(3/15),and 1 patient achieved stable disease(1/15),1 patient was lost to follow-up(1/15),1 patient was untreated(1/15),and 1 patient was progression of disease(1/15).Age,pathological subtype,sex,stage,β2-MG level,LDH level,and the using of rituximab were not correlated with the complete remission rate of the patients(P>0.05),while the IPI score was correlated with the recent complete remission rate(P<0.05).The median follow-up time was 19(1-38)months,10 patients survived,in which 6 cases were still in complete remission,and the median time to progression-free survival was 15(1-38)months.Conclusion:The first symptom of primary bone diffuse large B-cell lymphoma is bone pain,the main pathological subtype is Non-GCB,the optimal treatment is combined chemotherapy,and the IPI score is related to the prognosis of the treatment.

关 键 词：原发骨淋巴瘤 弥漫大B细胞淋巴瘤 临床特征 预后 

分 类 号：R738.1[医药卫生—肿瘤]